EGFR and proteasomes play a pivotal role in NSCLC development, and their inhibitors could be used in NSCLC treatment (Li et al., 2009; Liu et al., 2014; Floc’h et al., 2018; Tanimoto et al., 2021). Here, EGFR is linked to non-small cell lung carcinoma.